Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.66 |
| ▸ | HRH1 | P35367 | 1/20 | 0.60 |
| ▸ | APP | P05067 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | RAD52 | P43351 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6108904 | 0.94 | HRH3 (0.61) | HRH3HRH1 | |
| SCHEMBL6109362 | 0.90 | HRH3 (0.62) | HRH3HRH1 | |
| SCHEMBL6111863 | 0.89 | HRH3 (0.61) | HRH3HRH1 | |
| SCHEMBL6110561 | 0.88 | HRH3 (0.60) | HRH3HRH1 | |
| Hydrochloric Acid SCHEMBL6109021 | 0.87 | HRH3 (0.59) | HRH3HRH1 | |
| SCHEMBL6110005 | 0.87 | HRH3 (0.54) | HRH3HRH1 | |
| SCHEMBL6109941 | 0.85 | HRH3 (0.59) | HRH3HRH1 | |
| SCHEMBL6110931 | 0.85 | HRH3 (0.59) | HRH3HRH1 | |
| SCHEMBL6071172 | 0.84 | HRH3 (0.79) | HRH3HRH1ACHERAD52 | |
| SCHEMBL6110463 | 0.83 | HRH3 (0.88) | HRH3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167046-A1 | Histamine h3 receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2006-07-27 | — | — | US | disclosed |
| EP-1585731-A2 | HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATON AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004026837-A2 | HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATON AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167046-A1 | Histamine h3 receptor antagonists, preparation and therapeutic uses | HRH3, HRH4, HRH2 | HRH3 1/4885HRH1 4/4885APP 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.